Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Blood tests Fine-Tune leukemia drug combo to cut infection risk

NCT ID NCT07254611

First seen Dec 18, 2025 · Last updated May 24, 2026 · Updated 19 times

Summary

This study looked at 15 older adults with acute myeloid leukemia (AML) who were getting a standard drug combo (azacitidine or decitabine plus venetoclax). Because these drugs can lower infection-fighting white blood cells, patients often take an antifungal called posaconazole. The problem is posaconazole can raise venetoclax levels too high, causing more side effects. Researchers measured venetoclax in the blood to see how many patients reached a stable, safe level by day 12, aiming to guide proper dosing.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AML (ACUTE MYELOGENOUS LEUKEMIA) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Fondazione IRCCS Policlinico San Matteo

    Pavia, Lombardy, 27100, Italy

Conditions

Explore the condition pages connected to this study.